Advertisement

Comparison of Early Strut Coverage Between Zotarolimus- and Everolimus-Eluting Stents Using Optical Coherence Tomography

Published:October 04, 2012DOI:https://doi.org/10.1016/j.amjcard.2012.08.037
      There have been no optical coherence tomographic (OCT) data directly comparing the pattern of strut coverage between the 2 second-generation drug-eluting stents in the early period. The aim of this prospective study was to evaluate early strut coverage using optical coherence tomography 3 months after Resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) implantation in de novo coronary artery lesions. A total of 40 patients who were suitable for the OCT procedure and consented to the study protocol were randomized 1:1 to receive either ZES-R or EES. Among these patients, 35 stented lesions (18 ZES-R, 17 EES) in 34 patients were evaluated by optical coherence tomography immediately and 3 months after stent implantation. Neointimal hyperplasia thickness, percentage of uncovered struts, and the proportion of malapposed struts were measured at 1-mm intervals. An uncovered strut was defined as having a neointimal hyperplasia thickness of 0 μm. At the 3-month OCT evaluation, mean neointimal hyperplasia thickness (ZES-R vs EES 74 ± 41 vs 75 ± 35 μm, p = 0.89) and mean percentage of uncovered struts (ZES-R vs EES 6.2 ± 6.9 vs 4.7 ± 5.1%, p = 0.62) were not significantly different between the groups. The percentage of malapposed struts was also similar between the groups (0.7 ± 2.2% for ZES-R and 0.7 ± 1.7% for EES, p = 0.64). Thrombi were documented in 3 stents (1 [5.6%] in a ZES-R vs 2 [11.8%] in EES, p = 0.60). In conclusion, early stent strut coverage on the basis of serial OCT evaluation was comparable between ZES-R and EES 3 months after stent implantation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lange R.A.
        • Hillis L.D.
        Second-generation drug-eluting coronary stents.
        N Engl J Med. 2010; 362: 1728-1730
        • Meredith I.T.
        • Worthley S.
        • Whitbourn R.
        • Walters D.L.
        • McClean D.
        • Horrigan M.
        • Popma J.J.
        • Cutlip D.E.
        • DePaoli A.
        • Negoita M.
        • Fitzgerald P.J.
        • RESOLUTE Investigators
        Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.
        J Am Coll Cardiol Intv. 2009; 2: 977-985
        • Udipi K.
        • Melder R.J.
        • Chen M.
        • Cheng P.
        • Hezi-Yamit A.
        • Sullivan C.
        • Wong J.
        • Wilcox J.
        The next generation Endeavor Resolute stent: role of the BioLinx polymer system.
        Eurointervention. 2007; 3: 137-139
        • Stone G.W.
        • Rizvi A.
        • Newman W.
        • Mastali K.
        • Wang J.C.
        • Caputo R.
        • Doostzadeh J.
        • Cao S.
        • Simonton C.A.
        • Sudhir K.
        • SPIRIT IV Investigators
        Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
        N Engl J Med. 2010; 362: 1663-1674
        • Joner M.
        • Nakazawa G.
        • Finn A.V.
        • Quee S.C.
        • Coleman L.
        • Acampado E.
        • Wilson P.S.
        • Skorija K.
        • Cheng Q.
        • Xu X.
        • Gold H.K.
        • Kolodgie F.D.
        • Virmani R.
        Endothelial cell recovery between comparator polymer-based drug-eluting stents.
        J Am Coll Cardiol. 2008; 52: 333-342
        • Serruys P.W.
        • Silber S.
        • Garg S.
        • van Geuns R.J.
        • Richardt G.
        • Buszman P.E.
        • Kelbaek H.
        • van Boven A.J.
        • Hofma S.H.
        • Linke A.
        • Klauss V.
        • Wijns W.
        • Macaya C.
        • Garot P.
        • DiMario C.
        • Manoharan G.
        • Kornowski R.
        • Ischinger T.
        • Bartorelli A.
        • Ronden J.
        • Bressers M.
        • Gobbens P.
        • Negoita M.
        • van Leeuwen F.
        • Windecker S.
        Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
        N Engl J Med. 2010; 363: 136-146
        • Kim J.S.
        • Kim B.K.
        • Jang I.K.
        • Shin D.H.
        • Ko Y.G.
        • Choi D.
        • Hong M.K.
        • Cho Y.K.
        • Nam C.W.
        • Hur S.H.
        • Choi JH.
        • Song YB.
        • Hahn JY.
        • Choi SH.
        • Gwon HC.
        • Jang Y.
        Comparison of Neointimal Coverage Between Zotarolimus-Eluting Stent and Everolimus-Eluting Stent Using Optical Coherence Tomography (COVER OCT).
        Am Heart J. 2012; 163: 601-607
        • Kim B.K.
        • Kim J.S.
        • Park J.
        • Ko Y.G.
        • Choi D.
        • Jang Y.
        • Hong M.K.
        Comparison of optical coherence tomographic assessment between first- and second-generation drug-eluting stents.
        Yonsei Med J. 2012; 53: 524-529
        • Inoue T.
        • Shite J.
        • Yoon J.
        • Shinke T.
        • Otake H.
        • Sawada T.
        • Kawamori H.
        • Katoh H.
        • Miyoshi N.
        • Yoshino N.
        • Kozuki A.
        • Hariki H.
        • Hirata K.
        Optical coherence evaluation of everolimus-eluting stents 8 months after implantation.
        Heart. 2011; 97: 1379-1384
        • Takano M.
        • Inami S.
        • Jang I.K.
        • Yamamoto M.
        • Murakami D.
        • Seimiya K.
        • Ohba T.
        • Mizuno K.
        Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation.
        Am J Cardiol. 2007; 99: 1033-1038
        • Tearney G.J.
        • Regar E.
        • Akasaka T.
        • Adriaenssens T.
        • Barlis P.
        • Bezerra H.G.
        • Bouma B.
        • Bruining N.
        • Cho J.M.
        • Chowdhary S.
        • Costa M.A.
        • de Silva R.
        • Dijkstra J.
        • Di Mario C.
        • Dudek D.
        • Falk E.
        • Feldman M.D.
        • Fitzgerald P.
        • Garcia-Garcia H.M.
        • Gonzalo N.
        • Granada J.F.
        • Guagliumi G.
        • Holm N.R.
        • Honda Y.
        • Ikeno F.
        • Kawasaki M.
        • Kochman J.
        • Koltowski L.
        • Kubo T.
        • Kume T.
        • Kyono H.
        • Lam C.C.
        • Lamouche G.
        • Lee D.P.
        • Leon M.B.
        • Maehara A.
        • Manfrini O.
        • Mintz G.S.
        • Mizuno K.
        • Morel M.A.
        • Nadkarni S.
        • Okura H.
        • Otake H.
        • Pietrasik A.
        • Prati F.
        • Räber L.
        • Radu M.D.
        • Rieber J.
        • Riga M.
        • Rollins A.
        • Rosenberg M.
        • Sirbu V.
        • Serruys P.W.
        • Shimada K.
        • Shinke T.
        • Shite J.
        • Siegel E.
        • Sonoda S.
        • Suter M.
        • Takarada S.
        • Tanaka A.
        • Terashima M.
        • Thim T.
        • Uemura S.
        • Ughi G.J.
        • van Beusekom H.M.
        • van der Steen A.F.
        • van Es G.A.
        • van Soest G.
        • Virmani R.
        • Waxman S.
        • Weissman N.J.
        • Weisz G.
        • International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT)
        Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation.
        J Am Coll Cardiol. 2012; 59: 1058-1072
        • Finn A.V.
        • Joner M.
        • Nakazawa G.
        • Kolodgie F.
        • Newell J.
        • John M.C.
        • Gold H.K.
        • Virmani R.
        Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
        Circulation. 2007; 115: 2435-2441
        • Kume T.
        • Akasaka T.
        • Kawamoto T.
        • Ogasawara Y.
        • Watanabe N.
        • Toyota E.
        • Neishi Y.
        • Sukmawan R.
        • Sadahira Y.
        • Yoshida K.
        Assessment of coronary arterial thrombus by optical coherence tomography.
        Am J Cardiol. 2006; 97: 1713-1717
        • Farb A.
        • Burke A.P.
        • Kolodgie F.D.
        • Virmani R.
        Pathological mechanisms of fatal late coronary stent thrombosis in humans.
        Circulation. 2003; 108: 1701-1706
        • Cook S.
        • Wenaweser P.
        • Togni M.
        • Billinger M.
        • Morger C.
        • Seiler C.
        • Vogel R.
        • Hess O.
        • Meier B.
        • Windecker S.
        Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation.
        Circulation. 2007; 115: 2426-2434
        • Xie Y.
        • Takano M.
        • Murakami D.
        • Yamamoto M.
        • Okamatsu K.
        • Inami S.
        • Seimiya K.
        • Ohba T.
        • Seino Y.
        • Mizuno K.
        Comparison of neointimal coverage by optical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation.
        Am J Cardiol. 2008; 102: 27-31
        • Moore P.
        • Barlis P.
        • Spiro J.
        • Ghimire G.
        • Roughton M.
        • Di Mario C.
        • Wallis W.
        • Ilsley C.
        • Mitchell A.
        • Mason M.
        • Kharbanda R.
        • Vincent P.
        • Sherwin S.
        • Dalby M.
        A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents.
        J Am Coll Cardiol Intv. 2009; 2: 437-444
        • Gutiérrez-Chico J.L.
        • van Geuns R.J.
        • Regar E.
        • van der Giessen W.J.
        • Kelbæk H.
        • Saunamäki K.
        • Escaned J.
        • Gonzalo N.
        • di Mario C.
        • Borgia F.
        • Nüesch E.
        • García-García H.M.
        • Silber S.
        • Windecker S.
        • Serruys PW.
        Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial.
        Eur Heart J. 2011; 32: 2454-2463
        • Guagliumi G.
        • Ikejima H.
        • Sirbu V.
        • Bezerra H.
        • Musumeci G.
        • Lortkipanidze N.
        • Fiocca L.
        • Tahara S.
        • Vassileva A.
        • Matiashvili A.
        • Valsecchi O.
        • Costa M.
        Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the Long OCT study (Optical Coherence Tomography in Long Lesions).
        J Am Coll Cardiol Intv. 2011; 4: 778-785

      Linked Article